PE20140203A1 - Combinaciones farmaceuticas - Google Patents
Combinaciones farmaceuticasInfo
- Publication number
- PE20140203A1 PE20140203A1 PE2013000776A PE2013000776A PE20140203A1 PE 20140203 A1 PE20140203 A1 PE 20140203A1 PE 2013000776 A PE2013000776 A PE 2013000776A PE 2013000776 A PE2013000776 A PE 2013000776A PE 20140203 A1 PE20140203 A1 PE 20140203A1
- Authority
- PE
- Peru
- Prior art keywords
- methyl
- optor
- quinolin
- rapamycin
- imidazo
- Prior art date
Links
- -1 PYRIMIDINYL Chemical class 0.000 abstract 3
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 abstract 3
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 108091007960 PI3Ks Proteins 0.000 abstract 2
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 abstract 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical group 0.000 abstract 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 abstract 2
- 229960002930 sirolimus Drugs 0.000 abstract 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 abstract 2
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 abstract 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 abstract 1
- 230000003197 catalytic effect Effects 0.000 abstract 1
- SQQXRXKYTKFFSM-UHFFFAOYSA-N chembl1992147 Chemical compound OC1=C(OC)C(OC)=CC=C1C1=C(C)C(C(O)=O)=NC(C=2N=C3C4=NC(C)(C)N=C4C(OC)=C(O)C3=CC=2)=C1N SQQXRXKYTKFFSM-UHFFFAOYSA-N 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229940124669 imidazoquinoline Drugs 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 229960000235 temsirolimus Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
REFERIDA A UNA COMBINACION FARMACEUTICA QUE COMPRENDE: a) UN COMPUESTO DERIVADO DE IMIDAZOQUINOLINA INHIBIDOR DE CINASA DE FOSFATIDIL-INOSITOL-3 CATALITICA (PI3K)/OBJETIVO DE MAMIFERO DE RAPAMICINA (mTOR) DE FORMULA (I), DONDE R1 ES NAFTILO O FENILO OPCIONALMENTE SUSTITUIDOS CON HALOGENO, HALOALQUILO, ENTRE OTROS; R2 ES O O S; R3 ES ALQUILO C1-C7; R4 ES PIRIDILO, PIRIMIDINILO, QUINOLINILO, ENTRE OTROS; R5 ES H O HALOGENO; n ES 0 O 1; R6 ES OXIDO; R7 ES H O AMINO Y b) UN COMPUESTO ALOSTERICO INHIBIDOR DE mTOR TAL COMO RAPAMICINA RAD (SIROLIMUS), EVEROLIMUS (RAD001), CCI-779 Y DEFEROLIMUS (AP-23573/MK-8669). SON COMPUESTOS PREFERIDOS DE FORMULA (I): 2-METIL-2-[4-(3-METIL-2-OXO-8-QUINOLIN-3-IL-2,3-DIHIDRO-IMIDAZO-[4,5-c]-QUINOLIN-1-IL)-FENIL]-PROPIONITRILO, 8-(6-METOXI-PIRIDIN-3-IL)-3-METIL-1-(4-PIPERAZIN-1-IL-3-TRIFLUORO-METIL-FENIL)-1,3-DIHIDRO-IMIDAZO-[4,5-c]-QUINOLIN-2-ONA, ENTRE OTROS. DICHA COMBINACION ES UTIL EN EL TRATAMIENTO DE UNA ENFERMEDAD PROLIFERATIVA DEPENDIENTE DE LA CINASA mTOR
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38944510P | 2010-10-04 | 2010-10-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20140203A1 true PE20140203A1 (es) | 2014-02-28 |
Family
ID=44802399
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2013000776A PE20140203A1 (es) | 2010-10-04 | 2011-10-03 | Combinaciones farmaceuticas |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20130178479A1 (es) |
| EP (1) | EP2624831A1 (es) |
| JP (1) | JP2013538876A (es) |
| KR (1) | KR20130108330A (es) |
| CN (1) | CN103153305A (es) |
| AR (1) | AR083267A1 (es) |
| AU (1) | AU2011312372A1 (es) |
| BR (1) | BR112013008074A2 (es) |
| CA (1) | CA2812786A1 (es) |
| CL (1) | CL2013000895A1 (es) |
| CO (1) | CO6710908A2 (es) |
| EC (1) | ECSP13012541A (es) |
| MA (1) | MA34554B1 (es) |
| MX (1) | MX2013003833A (es) |
| NZ (1) | NZ608375A (es) |
| PE (1) | PE20140203A1 (es) |
| RU (1) | RU2013120357A (es) |
| SG (1) | SG188521A1 (es) |
| TW (1) | TW201217374A (es) |
| WO (1) | WO2012047775A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2611885T3 (es) | 2011-01-31 | 2017-05-11 | Novartis Ag | Derivados heterocíclicos novedosos |
| ES2570183T3 (es) * | 2011-02-16 | 2016-05-17 | Novartis Ag | Combinaciones de agentes terapéuticos para uso en el tratamiento de enfermedades neurodegenerativas |
| WO2013192367A1 (en) * | 2012-06-22 | 2013-12-27 | Novartis Ag | Neuroendocrine tumor treatment |
| WO2014028566A1 (en) * | 2012-08-16 | 2014-02-20 | Novartis Ag | Combination of pi3k inhibitor and c-met inhibitor |
| JO3377B1 (ar) * | 2013-03-11 | 2019-03-13 | Takeda Pharmaceuticals Co | مشتقات بيريدينيل وبيريدينيل مندمج |
| EA201792314A1 (ru) | 2015-05-20 | 2018-05-31 | Новартис Аг | Фармацевтическая комбинация эверолимуса и дактолисиба |
| GB201516504D0 (en) | 2015-09-17 | 2015-11-04 | Astrazeneca Ab | Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer |
| CN110114070A (zh) | 2016-11-23 | 2019-08-09 | 诺华公司 | 使用依维莫司(everolimus)、达托里昔布(dactolisib)或二者增强免疫反应的方法 |
| US10596165B2 (en) | 2018-02-12 | 2020-03-24 | resTORbio, Inc. | Combination therapies |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0510390D0 (en) * | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| EP1962839A4 (en) * | 2005-11-14 | 2010-08-25 | Ariad Pharma Inc | ADMINISTRATION OF A MNTOR INHIBITOR FOR THE TREATMENT OF PATIENTS WITH CANCER |
| CA2676786C (en) * | 2007-02-20 | 2015-01-27 | Novartis Ag | Imidazoquinolines as dual lipid kinase and mtor inhibitors |
-
2011
- 2011-09-30 AR ARP110103630A patent/AR083267A1/es unknown
- 2011-10-03 JP JP2013532854A patent/JP2013538876A/ja active Pending
- 2011-10-03 MA MA35783A patent/MA34554B1/fr unknown
- 2011-10-03 MX MX2013003833A patent/MX2013003833A/es unknown
- 2011-10-03 TW TW100135797A patent/TW201217374A/zh unknown
- 2011-10-03 RU RU2013120357/15A patent/RU2013120357A/ru not_active Application Discontinuation
- 2011-10-03 PE PE2013000776A patent/PE20140203A1/es not_active Application Discontinuation
- 2011-10-03 AU AU2011312372A patent/AU2011312372A1/en not_active Abandoned
- 2011-10-03 CN CN201180048544XA patent/CN103153305A/zh active Pending
- 2011-10-03 US US13/876,021 patent/US20130178479A1/en not_active Abandoned
- 2011-10-03 KR KR1020137008528A patent/KR20130108330A/ko not_active Application Discontinuation
- 2011-10-03 CA CA2812786A patent/CA2812786A1/en not_active Abandoned
- 2011-10-03 SG SG2013018254A patent/SG188521A1/en unknown
- 2011-10-03 WO PCT/US2011/054536 patent/WO2012047775A1/en active Application Filing
- 2011-10-03 EP EP11770611.9A patent/EP2624831A1/en not_active Withdrawn
- 2011-10-03 NZ NZ608375A patent/NZ608375A/en not_active IP Right Cessation
- 2011-10-03 BR BR112013008074A patent/BR112013008074A2/pt not_active Application Discontinuation
-
2013
- 2013-04-01 EC ECSP13012541 patent/ECSP13012541A/es unknown
- 2013-04-03 CL CL2013000895A patent/CL2013000895A1/es unknown
- 2013-04-08 CO CO13090543A patent/CO6710908A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| MA34554B1 (fr) | 2013-09-02 |
| NZ608375A (en) | 2014-08-29 |
| CA2812786A1 (en) | 2012-04-12 |
| EP2624831A1 (en) | 2013-08-14 |
| JP2013538876A (ja) | 2013-10-17 |
| AR083267A1 (es) | 2013-02-13 |
| BR112013008074A2 (pt) | 2016-06-14 |
| ECSP13012541A (es) | 2013-06-28 |
| TW201217374A (en) | 2012-05-01 |
| MX2013003833A (es) | 2013-06-28 |
| RU2013120357A (ru) | 2014-11-20 |
| CL2013000895A1 (es) | 2013-09-27 |
| WO2012047775A1 (en) | 2012-04-12 |
| KR20130108330A (ko) | 2013-10-02 |
| CO6710908A2 (es) | 2013-07-15 |
| SG188521A1 (en) | 2013-04-30 |
| US20130178479A1 (en) | 2013-07-11 |
| AU2011312372A1 (en) | 2013-04-04 |
| CN103153305A (zh) | 2013-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20140203A1 (es) | Combinaciones farmaceuticas | |
| CY1122712T1 (el) | ΧΡΗΣΗ ΠΑΡΑΓΩΓΩΝ ΠΥΡΑΖΟΛΟΠΥΡΙΜΙΔΙΝΗΣ ΓΙΑ ΤΗ ΘΕΡΑΠΕΙΑ ΣΧΕΤΙΚΩΝ ΜΕ PI3Kδ ΔΙΑΤΑΡΑΧΩΝ | |
| EA201390823A1 (ru) | ДВОЙНЫЕ ИНГИБИТОРЫ PI3 КИНАЗЫ/mTOR | |
| PE20170666A1 (es) | 2-(morfolin-4-il)-1,7-naftiridinas | |
| CY1119499T1 (el) | Ενωσεις 6,7-διυδροπυραζολο[1,5-α]πυραζιν-4(5η)-ονης και η χρηση τους ως αρνητικοι αλλοστερικοι τροποποιητες των υποδοχεων mglur2 | |
| MD4779B1 (ro) | Compuşi aril sau heteroaril biciclici condensaţi şi utilizarea acestora ca inhibitori IRAK4 | |
| CY1123616T1 (el) | 7-βενζυλ-4-(4-(τριφθορομεθυλ)βενζυλ)-1,2,6,7,8,9-εξαϋδροϊμιδαζο[1,2-α]πυριδο[3,4-ε]πυριμιδιν-5(4η)-ονη, και αλατα αυτης και χρηση αυτων στη θεραπεια | |
| PE20190656A1 (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 | |
| EA201690848A1 (ru) | Производные бициклического пиридила с конденсированными кольцами в качестве ингибиторов fgfr4 | |
| CL2013000351A1 (es) | Compuestos derivados de 2-(arilamino)-3h-imidazo[4,5-b]piridina-6-carboxamida; inhibidores de la prostaglandina e2 sintasa-1 microsomal (mpges-1) composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de medicamentos para el tratamiento de enfermedades inflamatorias. | |
| TR201911151T4 (tr) | Jak2 ve alk2 inhibitörleri ve bunların kullanım yöntemleri. | |
| NZ629025A (en) | Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists | |
| EA202090291A3 (ru) | Производные бипиразола в качестве ингибиторов jak | |
| PE20130376A1 (es) | [1,8]naftiridinas sustituidas por 2,4-diarilo como inhibidores de quinasas para uso contra el cancer | |
| UY34451A (es) | Derivados de uracilo como inhibidores de la quinasa axl y c-met | |
| MX2013005445A (es) | Pirazolopiridinas y el uso de pirazolopiridinas como inhibidores de tirosina cinasa 2 (tyk2). | |
| PE20141557A1 (es) | Derivado de pirazoloquinolina | |
| MY196172A (en) | Tricyclic Spiro Compound | |
| PE20141205A1 (es) | Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores de bace1 y/o bace2 | |
| NZ607527A (en) | Fused heteroaryls and their uses | |
| PH12016501699A1 (en) | 1,2-dihydro-3h-pyrrolo[1,2-c]imidazol-3-one derivatives and their use as antibacterial agents | |
| MD3532067T2 (ro) | Formă farmaceutică lipozomală pentru utilizare în tratamentul cancerului | |
| RU2012125152A (ru) | Способы и композиции, предназначенные для лечения солидных опухолей и других злокачественных новообразований | |
| PE20142366A1 (es) | Compuestos triazolo como inhibidores de pde 10 | |
| CL2014002048A1 (es) | Compuestos derivados de 4-(benzoimidazol-2-il)-tiazol y derivados aza relacionados; composicion farmaceutica; y uso en la prevencion y el tratamiento de trastornos autoinmunes, inflamatorios, enfermedades infecciosas, entre otras. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |